Budapest, Hungary

Erzsebet Walcz


Average Co-Inventor Count = 13.0

ph-index = 3

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 2008-2010

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Erzsebet Walcz: Innovator in Adenosine Receptor Ligands

Introduction

Erzsebet Walcz is a prominent inventor based in Budapest, Hungary. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of adenosine receptor ligands. With a total of 4 patents to her name, her work has garnered attention in the scientific community.

Latest Patents

One of her latest patents is titled "Triazolo-quinolin derivatives useful as adenosine receptor ligands." This invention relates to adenosine A receptor ligands of a specific general formula, focusing on antagonists and their various forms, including salts, solvates, and isomers. The patent also discusses the pharmaceutical compositions containing these compounds and their preparation methods. Another notable patent is "Imidazoquinoline derivatives as adenosine A3 receptor ligands." This invention details a compound of a defined formula, its preparation, and its use as an adenosine A receptor ligand, preferably as an antagonist.

Career Highlights

Erzsebet Walcz is currently employed at Sanofi-Aventis, a leading global biopharmaceutical company. Her work at Sanofi-Aventis has allowed her to focus on innovative research and development in the pharmaceutical sector.

Collaborations

Throughout her career, Erzsebet has collaborated with notable colleagues, including Peter Aranyi and Laszlo Balazs. These collaborations have contributed to her success and the advancement of her research.

Conclusion

Erzsebet Walcz is a distinguished inventor whose work in adenosine receptor ligands has made a significant impact in the pharmaceutical industry. Her innovative patents and collaborations highlight her dedication to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…